Galectin Therapeutics reported $-83.87M in Equity Capital and Reserves for its fiscal quarter ending in June of 2024.





Equity Capital And Reserves Change Date
AbbVie USD -5.94B 721M Jun/2026
Bristol-Myers Squibb USD 22.32B 2.25B Jun/2026
Galectin Therapeutics USD -83.87M 11.06M Jun/2024
Gilead Sciences USD 11.74B 11.77B Jun/2026
Immunic USD 151.23M 157.91M Mar/2026
Incyte USD 6.34B 721.58M Jun/2026
Merck USD 45.88B 6.73B Mar/2026